文献速递肝病消化道肿瘤与早癌

阻断H1/H2组胺受体抑制Mdr2-/-小鼠损伤/纤维化及人胆管癌肿瘤发生

Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis.
PubMed 文献 · Hepatology · 2018-06-01

研究在Mdr2-/-小鼠和Nu/nu小鼠胆管癌模型中观察长期阻断H1/H2组胺受体对原发性硬化性胆管炎(PSC)相关胆管损伤、纤维化及胆管癌生长的影响,并在体外评价对人肝胆星状细胞和胆管癌细胞的作用;结果显示H1/H2受体拮抗剂减轻小鼠肝和胆管损伤及纤维化,并减少肿瘤生长、血管生成和上皮-间质转化,作者认为组胺受体阻断剂可能对PSC及胆管癌有治疗作用。

要点

  • H1/H2组胺受体及肥大细胞在人类PSC和胆管癌中增多。
  • H1/H2受体拮抗剂(单用或联用)减轻Mdr2-/-小鼠肝和胆管损伤及纤维化。
  • H1/H2受体拮抗剂减少小鼠胆管癌生长、血管生成和上皮-间质转化,作者认为可能对PSC和胆管癌有治疗作用。

核心结论

  • 抑制H1/H2组胺受体可逆转PSC相关损伤,并减少胆管癌生长、血管生成和上皮-间质转化;作者认为因PSC患者有发生胆管癌的风险,使用组胺受体阻断剂可能对这类疾病有治疗作用。

研究设计与样本

  • 野生型和Mdr2-/-小鼠通过渗透泵给予生理盐水、美吡拉敏或雷尼替丁(10 mg/kg体重/天)或美吡拉敏/雷尼替丁联合治疗4周。
  • Nu/nu小鼠后肢侧面植入Mz-ChA-1细胞后给予生理盐水、美吡拉敏或雷尼替丁,测量肿瘤生长。
  • 体外培养人肝胆星状细胞评估H1HR和H2HR表达,培养胆管细胞和胆管癌细胞系给予生理盐水、美吡拉敏或雷尼替丁(25 μM)后评估增殖、血管生成、上皮-间质转化及潜在信号机制。

主要发现

  • 在人类PSC和胆管癌中H1/H2HR及肥大细胞存在增加。
  • 与生理盐水治疗相比,H1/H2HR拮抗剂(单用或联合)治疗的Mdr2-/-小鼠肝和胆管损伤及纤维化减少。
  • H1/H2HR拮抗剂减少肿瘤生长、血清组胺、血管生成和上皮-间质转化。
  • 体外H1/H2HR阻断剂减少胆管增殖,胆管癌细胞增殖、血管生成、上皮-间质转化和迁移减少。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary sclerosing cholangitis (PSC) patients are at risk of developing cholangiocarcinoma (CCA). We have shown that (1) histamine increases biliary hyperplasia through H1/H2 histamine receptors (HRs) and (2) histamine levels increase and mast cells (MCs) infiltrate during PSC and CCA. We examined the effects of chronic treatment with H1/H2HR antagonists on PSC and CCA. Wild-type and multidrug-resistant knockout (Mdr2-/- ) mice were treated by osmotic minipumps with saline, mepyramine, or ranitidine (10 mg/kg body weight/day) or a combination of mepyramine/ranitidine for 4 weeks. Liver damage was assessed by hematoxylin and eosin. We evaluated (1) H1/H2HR expression, (2) MC presence, (3) L-histidine decarboxylase/histamine axis, (4) cholangiocyte proliferation/bile duct mass, and (5) fibrosis/hepatic stellate cell activation. Nu/nu mice were implanted with Mz-ChA-1 cells into the hind flanks and treated with saline, mepyramine, or ranitidine. Tumor growth was measured, and (1) H1/H2HR expression, (2) proliferation, (3) MC activation, (4) angiogenesis, and (5) epithelial-mesenchymal transition (EMT) were evaluated. In vitro, human hepatic stellate cells were evaluated for H1HR and H2HR expression. Cultured cholangiocytes and CCA lines were treated with saline, mepyramine, or ranitidine (25 μM) before evaluating proliferation, angiogenesis, EMT, and potential signaling mechanisms. H1/H2HR and MC presence increased in human PSC and CCA. In H1/H2HR antagonist (alone or in combination)-treated Mdr2-/- mice, liver and biliary damage and fibrosis decreased compared to saline treatment. H1/H2HR antagonists decreased tumor growth, serum histamine, angiogenesis, and EMT. In vitro, H1/H2HR blockers reduced biliary proliferation, and CCA cells had decreased proliferation, angiogenesis, EMT, and migration. Conclusion: Inhibition of H1/H2HR reverses PSC-associated damage and decreases CCA growth, angiogenesis, and EMT; because PSC patients are at risk of developing CCA, using HR blockers may be therapeutic for these diseases. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kennedy L, Hargrove L, Demieville J, et al. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis. Hepatology. 2018. PMID: 29601088. doi:10.1002/hep.29898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。